Trial Profile
A Phase 2, Open-Label, Randomized, Non-Comparative Study With Preliminary Dose Finding to Evaluate eFT508 Monotherapy or eFT508 in Combination With Avelumab in Subjects With Microsatellite Stable Relapsed or Refractory Colorectal Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Avelumab (Primary) ; Tomivosertib (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Effector Therapeutics
- 16 Jul 2019 Status changed from active, no longer recruiting to completed.
- 03 Jun 2019 Safety results published in conjunction with 55th Annual Meeting of the American Society of Clinical Oncology (2019).
- 20 Aug 2018 Status changed from recruiting to active, no longer recruiting.